×

Juno Therapeutics (Nasdaq: JUNO) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO

ADVISORY, Dec. 19, 2014 (GLOBE NEWSWIRE) --

What:

Juno Therapeutics (Nasdaq:JUNO) will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO), which will occur today, December 19. Juno is focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer.

In honor of the occasion, Hans Bishop, CEO & President will ring the Opening Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Friday, December 19, 2014 – 9:15 a.m. to 9:30 a.m. ET

Juno Therapeutics Media Contacts:
Andreas Marathovouniotis
(212) 301-7174
amarathis@w2ogroup.com

Nasdaq MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A webcast of the Nasdaq Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Juno Therapeutics (Nasdaq:JUNO):

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world’s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.business.nasdaq.com.

-NDAQA-

Source:The NASDAQ OMX Group, Inc.